On the 30th anniversary of its aid-to-Tibet program, Qizheng Tibetan Medicine has once again advanced in the "Top 100 Chinese Traditional Chinese Medicine Enterprises 2023" ranking.

On the occasion of the 30th anniversary of the nationwide paired assistance to Tibet, as a shining enterprise contributing to Tibet’s development, Qizheng Tibetan Medicine ranked 28th on the “2023 China Top 100 Chinese Medicine Enterprises List.” The ranking has steadily climbed for three consecutive years. This list is part of the “Top 100 Chinese Pharmaceutical Industry Series,” recently and prominently released by MiNei.com—the leading platform for pharmaceutical and healthcare information in China. It is reported that the list focuses on the innovation-driven forces and professional promotion capabilities of pharmaceutical companies, ultimately conducting quantitative analysis based on MiNei.com’s exclusive data from three major terminals and six key market segments, ensuring a more scientific and rigorous selection process and showcasing the outstanding excellence of pharmaceutical brands.

Tibetan medicine is a magnificent treasure trove safeguarding human health—a boundless resource upon which Qizheng Tibetan Medicine relies for its development and brand building. Against the backdrop of the “National 87 Assault Plan,” in 1995, Qizheng Tibetan Medicine became the first enterprise in the history of China’s aid-to-Tibet program, establishing itself in Linzhi, Tibet. With deep reverence for and a sincere commitment to promoting the wisdom of Tibetan medicine and serving the broad masses of people, Qizheng Tibetan Medicine has always been committed to enriching and expanding the substance of its development, continuously exploring how to harness traditional wisdom in response to growing demands for greater health, thereby demonstrating genuine care for life. Upholding the principle of sustainable development, we strive to create high-quality products and exceptional services.

In 2023, the company was listed on the “2023 Health Industry Brand Value List” by the China Pharmaceutical Industry Association, with a brand value of 2.87 billion yuan. The company was also named among the “Top 20 Chinese Traditional Medicine Enterprises with the Greatest International Influence.” Its product, Qizheng® Pain Relief Plaster, received the honors of “2023 China Over-the-Counter Drug Golden Product” and “Brand with Significant Influence in the Pharmaceutical Industry.” Both Qizheng® Pain Relief Plaster and Qizheng® Iron Hammer Pain Relief Ointment were included in the “China Household Essential Medicines List—Top Brands for Topical Pain Relievers,” while Zhuopanlin® Ten-Flavor Gentian Flower Granules were featured in the “China Household Essential Medicines List—Top Brands for Cough and Phlegm Relief.”

Qizheng Tibetan Medicine adheres to the guiding principle of “rooted in classics, grounded in clinical practice, driven by technological innovation, enhancing therapeutic efficacy, and promoting medical integration.” It prioritizes the selection of time-tested classic prescriptions and clinically proven formulas for new drug development, focusing on innovations in dosage forms, expansion of new indications, development of novel delivery methods, and harnessing clinical value through the integration of Tibetan, Chinese, and Western medicine. By building an innovation and sharing platform, we continuously promote the development of the Tibetan medicine industry. Innovation-led initiatives are filling the gap in technological advancement within ethnic medicine enterprises. ， The company currently operates two national-local joint key laboratories and holds 148 patents, including 130 invention patents. It has been recognized as one of the first batch of National Innovative Enterprises and a Key High-Tech Enterprise under the National Torch Program. In 2021, it was designated as a National Demonstration Enterprise for Technological Innovation, becoming one of only six pharmaceutical companies listed on the roster. In 2023, the company undertook the national key R&D program project titled “Demonstration Development Research on the Treatment of Baimai Disease—a Major Tibetan Medical Condition—by the Classic Tibetan Medicines Ruyi Zhenbao Tablets and Baimai Ointment.” After three years of work, the project successfully passed the national acceptance inspection.

Qizheng Tibetan Medicine adheres to the concept of green development, setting a benchmark for pharmaceutical manufacturing prowess and striving to achieve the dual goals of resource conservation and environmental protection. In the inheritance and innovative development of traditional medicine, Qizheng has taken the lead in applying cutting-edge technologies to Tibetan medicinal preparations. It has pioneered original preparation techniques, developed a uniquely innovative wet-application patch dosage form, created automated core-forming technology for pill production, and engineered three successive iterations of the Qizheng Pain-Relieving Patch—a quintessential example of innovation that preserves and enhances the distinctive external therapeutic bath treatments characteristic of Tibetan medicine. By leveraging modern vacuum freeze-drying and wet-application processes, Qizheng continuously innovates and improves its processes and equipment, even going so far as to develop an automated patch-manufacturing machine that enables fully automated production of topical patches. As a result, Qizheng has obtained more than ten patented technologies.

Qizheng Tibetan Medicine has consistently upheld the tradition of cultivating and processing Tibetan medicinal herbs, while also adopting cutting-edge domestic and international technologies and quality-control standards to overcome technical challenges in Tibetan medicine production. This approach has significantly enhanced drug quality and ensured the safety and efficacy of patient treatments. Among Qizheng Tibetan Medicine’s products, a topical moist dressing plaster used for pain relief has become a treasured remedy widely embraced by Chinese physicians for addressing injuries and pain. For four consecutive years, this major Chinese herbal medicine product has achieved annual sales exceeding one billion yuan. The product has been awarded the Second Prize for National Scientific and Technological Progress, setting a classic example that seamlessly blends tradition with innovation and establishing Qizheng Tibetan Medicine as an outstanding brand that has successfully integrated scientific rigor with market-oriented strategies. Currently, 24 core products—including the renowned Xiaotong Plaster—have been included in the National Essential Medicines List; 70 products are listed in the “National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2023 Edition)”; 36 products have been incorporated into local provincial-level medical insurance catalogs; 49 products are part of local essential medicine lists; and 2 products have been added to the National Emergency (Rescue) Medicines List.

While focusing on the field of musculoskeletal pain relief, the company is also expanding into areas such as respiratory care, cardiovascular and cerebrovascular health, and pediatric and women’s healthcare. It has launched a variety of products including pain-relief patches, Tiebangchui pain-relief tablets, Qingpeng ointment, Bai Mai ointment, Shiwai Longdan Hua capsules/granules, and Rhodiola rosea oral liquid. This diverse product portfolio provides patients with comprehensive solutions for various diseases.

Qizheng Tibetan Medicine places great importance on evidence-based research. By systematically collecting and analyzing clinical practice data on the company’s products, we rigorously evaluate their efficacy and safety, thereby helping our products gain inclusion in various clinical practice guidelines and consensus statements. This provides a scientific basis for clinical decision-making and, in turn, offers patients higher-quality treatment options.